ReShape Lifesciences is a technology company.
ReShape Lifesciences has raised $3.0M across 1 funding round.
ReShape Lifesciences has raised $3.0M in total across 1 funding round.
ReShape Lifesciences Inc. is a physician-led medical device company developing minimally invasive technologies and services to treat obesity and metabolic diseases, serving patients seeking alternatives to invasive bariatric surgeries like gastric bypass or sleeve gastrectomy.[1][2][3] Its core products include the Lap-Band (an adjustable gastric band for long-term weight loss), ReShape Vest System (an investigational laparoscopic device that wraps the stomach to reduce volume), Obalon Balloon System (for adults with BMI 30-40), and ReShapeCare (a virtual telehealth coaching program for sustained lifestyle changes).[1][3][4] The company addresses the global obesity epidemic by offering patient-friendly, non-anatomy-altering options backed by clinical evidence, with recent growth shown in Q3 2024 revenue up 16.6% sequentially and 6.4% year-over-year.[2]
Founded in 2002, ReShape Lifesciences initially focused on minimally invasive obesity treatments, evolving through mergers like the 2019 combination with Obalon Therapeutics, after which Obalon was renamed ReShape Lifesciences Inc.[1][2] The company went public via IPO in 2016 and is headquartered in Irvine, California (with early roots in San Clemente), employing about 47 people.[2][3] Pivotal moments include establishing a global Scientific Advisory Board in early 2023 to guide evidence-based growth and product development, alongside a history of over 1 million Lap-Band implants worldwide, building on 25 years of clinical data.[1][4]
ReShape Lifesciences rides the surging demand for obesity treatments amid rising global rates of metabolic disease, fueled by GLP-1 drugs like semaglutide but addressing gaps in durable, non-pharmacological options.[1][3] Timing aligns with post-pandemic health awareness and insurance expansions for bariatric alternatives, positioning minimally invasive devices as scalable bridges between meds and surgery in a market projected to grow with aging populations and tech-enabled telehealth.[2][4] It influences the ecosystem by pioneering physician-endorsed programs that integrate virtual coaching, potentially expanding access via reimbursements and collaborations, while competing in a fragmented space of device makers and digital health platforms.[1][4]
ReShape's momentum—marked by three straight quarters of revenue growth and new product pipelines—signals potential acceleration through R&D, M&A, and evidence expansion via its Scientific Advisory Board.[1][2] Trends like hybrid device-digital therapies and personalized metabolic care will shape its path, possibly amplifying influence if it captures share from surgical dominance amid GLP-1 evolution. Watch for commercialization wins with ReShape Vest and global Lap-Band scaling, tying back to its core as a differentiated obesity innovator.[1][3]
ReShape Lifesciences has raised $3.0M in total across 1 funding round.
ReShape Lifesciences's investors include 4See Ventures, New Leaf Venture Partners, Casey Tansey.
ReShape Lifesciences has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in August 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2007 | $3.0M Series A | 4See Ventures, New Leaf Venture Partners, Casey Tansey |